Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

ASCO: Lung cancer screening by low-dose computed tomography results in high rate of false positives

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Published: 18 Jun 2009

Views: 13500

Rating:

Save

Dr. Jennifer M. Croswell - National Institutes of Health, Bethesda, Maryland, USA

ASCO press conference: A new study finds that lung cancer screening using low-dose computed tomography results in a high rate of false positives and significant follow-up testing.

Categories:
Lung & pleura

Related Videos

Blood test may identify patients with non-small cell lung cancer subtype who...

Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy ( Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA )

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows...

Dr Yan Zhang - Sichuan University, Chengdu, China

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC ( Dr Yan Zhang - Sichuan University, Chengdu, China )

Twice-daily chemoradiation remains the standard of care in limited stage small...

Dr Gerard Walls - Queen's University Belfast, Belfast, Northern Ireland

Twice-daily chemoradiation remains the standard of care in limited stage small-cell lung cancer ( Dr Gerard Walls - Queen's University Belfast, Belfast, Northern Ireland )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

What's new on ADCs in management of advanced NSCLC

Dr David Planchard - Institute Gustave Roussy, Villejuif, France

What's new on ADCs in management of advanced NSCLC ( Dr David Planchard - Institute Gustave Roussy, Villejuif, France )

Treatment of metastatic NSCLC without PD-L1 expression and without oncogene...

Dr Antonio Passaro - European Institute of Oncology, Milan, Italy

Treatment of metastatic NSCLC without PD-L1 expression and without oncogene addiction ( Dr Antonio Passaro - European Institute of Oncology, Milan, Italy )

ESMO 2023: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India

Lung Cancer ( Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India )

More from ecancer